Droxinavir

Droxinavir (also known as SC 55389A) was an experimental protease inhibitor researched by Pharmacia as a treatment for HIV infection. Its research and development was discontinued on March 06, 1995.[1]

Droxinavir
Names
IUPAC name
3-tert-butyl-1-[(2R,3S)-3-[(2S)-3,3-dimethyl-2-[2-(methylamino)acetamido]butyramido]-2-hydroxy-4-phenylbutyl-1-isopentylurea
Other names
SC 55389A
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
Properties
C29H51N5O4
Molar mass 533.75 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N (what is YN ?)
Infobox references

References

  1. "Drug Profile: Droxinavir". AdisInsight. Adis International Ltd, part of Springer Science+Business Media. Retrieved 23 November 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.